The Journal of Immunology, Vol 156, Issue 10 3821-3827, Copyright © 1996 by American Association of Immunologists

ARTICLES

Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules

S Baskar, VK Clements, LH Glimcher, N Nabavi and S Ostrand-Rosenberg
Department of Biological Sciences, University of Maryland, Baltimore 21228 USA.

Many tumor cells that have been transfected with genes encoding B7 costimulatory molecules become effective cellular vaccines against wild- type tumor. The improved immunity is dependent on newly induced tumor- specific CD8+ and/or CD4+ T cells and presumably occurs because the B7 transfectants provide the requisite second signal for activation of T cells in conjunction with tumor cell-presented MHC class I/tumor peptide and/or MHC class II/tumor peptide complexes, respectively. Since B7 expression is such a potent enhancer of tumor immunity, and yet some tumors are immunogenic in the absence of B7 transfection, we have used class I+ class-II-transfected tumors to investigate whether costimulatory molecules are also involved in rejection of immunogenic, non-B7-transfected tumor. Blocking studies with B7 mAbs demonstrate that induction of tumor immunity in naive mice requires B7-1 and/or B7- 2 expression, while experiments with tumor-primed mice indicate that once antitumor immunity is established, expression of B7 is not necessary. Flow cytometry analyses demonstrate that costimulatory molecules are expressed by the tumor cells via an in vivo induction process. Experiments with class II genes with truncated cytoplasmic tails indicate that the cytoplasmic region of the tumor-expressed class II heterodimer is involved in induction of B7. We therefore conclude that for this class I+ class II-transfected tumor, generation of tumor immunity requires induction of tumor cell-encoded B7 molecules that are mediated by the cytoplasmic region of the transfected class II heterodimer.

This article has been cited by other articles:

				B. P. Dolan, T. P. Phelan, D. Ilkovitch, L. Qi, W. F. Wade, T. M. Laufer, and S. Ostrand-Rosenberg Invariant Chain and the MHC Class II Cytoplasmic Domains Regulate Localization of MHC Class II Molecules to Lipid Rafts in Tumor Cell-Based Vaccines J. Immunol., January 15, 2004; 172(2): 907 - 914. [Abstract] [Full Text] [PDF]

				S. P. Murphy, R. Holtz, N. Lewandowski, T. B. Tomasi, and H. Fuji DNA Alkylating Agents Alleviate Silencing of Class II Transactivator Gene Expression in L1210 Lymphoma Cells J. Immunol., September 15, 2002; 169(6): 3085 - 3093. [Abstract] [Full Text] [PDF]

				S. Suvas, V. Singh, S. Sahdev, H. Vohra, and J. N. Agrewala Distinct Role of CD80 and CD86 in the Regulation of the Activation of B Cell and B Cell Lymphoma J. Biol. Chem., March 1, 2002; 277(10): 7766 - 7775. [Abstract] [Full Text] [PDF]

				H.-W. Mittrucker, M. Kursar, A. Kohler, R. Hurwitz, and S. H. E. Kaufmann Role of CD28 for the Generation and Expansion of Antigen-Specific CD8+ T Lymphocytes During Infection with Listeria monocytogenes J. Immunol., November 15, 2001; 167(10): 5620 - 5627. [Abstract] [Full Text] [PDF]

				A. Osborne, H. Zhang, W.-M. Yang, E. Seto, and G. Blanck Histone Deacetylase Activity Represses Gamma Interferon-Inducible HLA-DR Gene Expression following the Establishment of a DNase I-Hypersensitive Chromatin Conformation Mol. Cell. Biol., October 1, 2001; 21(19): 6495 - 6506. [Abstract] [Full Text] [PDF]

				L. Qi, J.-M. Rojas, and S. Ostrand-Rosenberg Tumor Cells Present MHC Class II-Restricted Nuclear and Mitochondrial Antigens and Are the Predominant Antigen Presenting Cells In Vivo J. Immunol., November 15, 2000; 165(10): 5451 - 5461. [Abstract] [Full Text] [PDF]

				G. W. Hull, M. A. McCurdy, Y. Nasu, C. H. Bangma, G. Yang, S. Shimura, H.-M. Lee, J. Wang, J. Albani, S. Ebara, et al. Prostate Cancer Gene Therapy: Comparison of Adenovirus-mediated Expression of Interleukin 12 with Interleukin 12 plus B7-1 for in Situ Gene Therapy and Gene-modified, Cell-based Vaccines Clin. Cancer Res., October 1, 2000; 6(10): 4101 - 4109. [Abstract] [Full Text]

				J. A. Harton and J. P.-Y. Ting Class II Transactivator: Mastering the Art of Major Histocompatibility Complex Expression Mol. Cell. Biol., September 1, 2000; 20(17): 6185 - 6194. [Full Text]

				A. D. Weinberg, M.-M. Rivera, R. Prell, A. Morris, T. Ramstad, J. T. Vetto, W. J. Urba, G. Alvord, C. Bunce, and J. Shields Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity J. Immunol., February 15, 2000; 164(4): 2160 - 2169. [Abstract] [Full Text] [PDF]

				B. Wang, R. Maile, R. Greenwood, E. J. Collins, and J. A. Frelinger Naive CD8+ T Cells Do Not Require Costimulation for Proliferation and Differentiation into Cytotoxic Effector Cells J. Immunol., February 1, 2000; 164(3): 1216 - 1222. [Abstract] [Full Text] [PDF]

				H. Zhang, A. T. Shepherd, D. D. Eason, S. Wei, J. I. Diaz, J. Y. Djeu, G. D. Wu, and G. Blanck Retinoblastoma Protein Expression Leads to Reduced Oct-1 DNA Binding Activity and Enhances Interleukin-8 Expression Cell Growth Differ., July 1, 1999; 10(7): 457 - 465. [Abstract] [Full Text]

				R. N. L. Motte, A. H. Sharpe, J. A. Bluestone, and M. B. Mokyr Host B7-1 and B7-2 Costimulatory Molecules Contribute to the Eradication of B7-1-Transfected P815 Tumor Cells Via a CD8+ T Cell-Dependent Mechanism J. Immunol., April 15, 1999; 162(8): 4817 - 4823. [Abstract] [Full Text] [PDF]

				R. N. La Motte, A. H. Sharpe, J. A. Bluestone, and M. B. Mokyr Importance of B7-1-Expressing Host Antigen-Presenting Cells for the Eradication of B7-2 Transfected P815 Tumor Cells J. Immunol., December 15, 1998; 161(12): 6552 - 6558. [Abstract] [Full Text] [PDF]

				T. Mutis, E. Schrama, C. J.M. Melief, and E. Goulmy CD80-Transfected Acute Myeloid Leukemia Cells Induce Primary Allogeneic T-Cell Responses Directed at Patient Specific Minor Histocompatibility Antigens and Leukemia-Associated Antigens Blood, September 1, 1998; 92(5): 1677 - 1684. [Abstract] [Full Text] [PDF]

				M. B. Mokyr, T. V. Kalinichenko, L. Gorelik, and J. A. Bluestone Importance of the B7-2 Molecule for Low Dose Melphalan-Induced Acquisition of Tumor-Eradicating Immunity by Mice Bearing a Large MOPC-315 Tumor J. Immunol., February 15, 1998; 160(4): 1866 - 1874. [Abstract] [Full Text] [PDF]

				T. D. Armstrong, V. K. Clements, and S. Ostrand-Rosenberg MHC Class II-Transfected Tumor Cells Directly Present Antigen to Tumor-Specific CD4+ T Lymphocytes1 J. Immunol., January 15, 1998; 160(2): 661 - 666. [Abstract] [Full Text] [PDF]